Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Finding appropriate doses for HER2 positive breast cancers

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 982

Dr Mariana Chavez-MacGregor - MD Anderson Cancer Center, Houston, USA

Dr MacGregor speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about therapy escalation/deescalation for patients with HER2 positive breast cancer.

She summarises the discussions from the session, noting the key role of pertuzumab and neratinib as new medicines to advance on the gains seen from trastuzumab therapy.

In de-escalation, Dr MacGregor discusses the potential of shorter trastuzumab or combined therapy regimens as a way of delivering sufficient care with no unnecessary toxicity.

For more on the Extenet trial, watch our interview with Prof Miguel Martin at ESMO 2017.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation